LONDON, UK. 2/11/21:  Baseimmune closes $4.8m 

Baseimmune closes $4.8m funding round to future-proof vaccines

Biotech startup Baseimmune, a spin-out from Imperial College, has raised $4.8m to develop the next generation of universal vaccines to protect against human and animal health threats (including malaria and COVID). Baseimmune’s vaccine design algorithm creates synthetic ‘pick and mix’ antigens which allows for recognition of current and future iterations of pathogens. 

The investment round this November, led by Hoxton Ventures and with Creator Fund, Cherry Ventures, Best Ventures and Maki.vc, will support the company to develop more vaccines and expand into additional disease types.